BACKGROUND/AIMS: Certain host genetic polymorphisms reportedly affect the likelihood of a sustained virological response (SVR) to interferon treatment in subjects infected with hepatitis C virus (HCV). As part of the HALT-C trial we evaluated genetic associations among patients infected with HCV genotype 1 who had failed previous interferon treatment. METHODS: SVR was determined 24 weeks after completing treatment with pegylated interferon alfa-2a and ribavirin. Eight single nucleotide polymorphisms (SNPs) were selected on the basis of previously reported associations with treatment response. Genotypes were assessed by polymerase chain reaction-based assays. The percentage of patients who achieved SVR was determined for each genotype and for an IL10 promoter diplotype. RESULTS: Among 637 non-Hispanic Caucasian patients there were no significant associations between genotype for any individual SNP (IL10-1082, IL10-592, TNF-308, TNF-238, TGFB1 codon 25, CCL2-2518, EPHX1 codon 113 and AGT-6) and SVR, but SVR was more common among the patients who were homozygous for the ACC IL10 promoter diplotype (adjusted odds ratio, 3.24; 95% confidence interval, 1.33-7.78; p=0.001). CONCLUSIONS: Among non-Hispanic Caucasian patients treated with peginterferon and ribavirin after failing previous treatment with interferon, homozygosity for the ACC IL10 promoter diplotype was associated with SVR.
BACKGROUND/AIMS: Certain host genetic polymorphisms reportedly affect the likelihood of a sustained virological response (SVR) to interferon treatment in subjects infected with hepatitis C virus (HCV). As part of the HALT-C trial we evaluated genetic associations among patients infected with HCV genotype 1 who had failed previous interferon treatment. METHODS: SVR was determined 24 weeks after completing treatment with pegylated interferon alfa-2a and ribavirin. Eight single nucleotide polymorphisms (SNPs) were selected on the basis of previously reported associations with treatment response. Genotypes were assessed by polymerase chain reaction-based assays. The percentage of patients who achieved SVR was determined for each genotype and for an IL10 promoter diplotype. RESULTS: Among 637 non-Hispanic Caucasian patients there were no significant associations between genotype for any individual SNP (IL10-1082, IL10-592, TNF-308, TNF-238, TGFB1 codon 25, CCL2-2518, EPHX1 codon 113 and AGT-6) and SVR, but SVR was more common among the patients who were homozygous for the ACC IL10 promoter diplotype (adjusted odds ratio, 3.24; 95% confidence interval, 1.33-7.78; p=0.001). CONCLUSIONS: Among non-Hispanic Caucasian patients treated with peginterferon and ribavirin after failing previous treatment with interferon, homozygosity for the ACC IL10 promoter diplotype was associated with SVR.
Authors: W Klein; A Tromm; T Griga; H Fricke; C Folwaczny; M Hocke; K Eitner; M Marx; M Runte; J T Epplen Journal: Electrophoresis Date: 2000-11 Impact factor: 3.535
Authors: E E Powell; C J Edwards-Smith; J L Hay; A D Clouston; D H Crawford; C Shorthouse; D M Purdie; J R Jonsson Journal: Hepatology Date: 2000-04 Impact factor: 17.425
Authors: M P Manns; J G McHutchison; S C Gordon; V K Rustgi; M Shiffman; R Reindollar; Z D Goodman; K Koury; M Ling; J K Albrecht Journal: Lancet Date: 2001-09-22 Impact factor: 79.321
Authors: Stacey A Rizza; Nathan W Cummins; David N Rider; Sahar Saeed; Marina B Klein; Andrew D Badley Journal: AIDS Date: 2010-11-13 Impact factor: 4.177
Authors: Tania Mara Welzel; Timothy R Morgan; Herbert L Bonkovsky; Deepa Naishadham; Ruth M Pfeiffer; Elizabeth C Wright; Amy A Hutchinson; Andrew T Crenshaw; Arman Bashirova; Mary Carrington; Myhanh Dotrang; Richard K Sterling; Karen L Lindsay; Robert J Fontana; William M Lee; Adrian M Di Bisceglie; Marc G Ghany; David R Gretch; Stephen J Chanock; Raymond T Chung; Thomas R O'Brien Journal: Hepatology Date: 2009-06 Impact factor: 17.425
Authors: Kristin K Snow; Margaret C Bell; Anne M Stoddard; Teresa M Curto; Elizabeth C Wright; Jules L Dienstag Journal: Trials Date: 2014-05-07 Impact factor: 2.279